YIDU TECH (02158) announced that its affiliated company, Tianjin Happy Life Technology Co., Ltd., has successfully secured the Phase III clinical research project for recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. The total project value amounts to approximately RMB 55.8176 million.

As a leading driver of AI medical transformation in China, YIDU TECH upholds the mission of "making precision medicine accessible to everyone" and develops professional, efficient, precise, and inclusive medical artificial intelligence products and solutions. Based on the company's proprietary core algorithm engine YiduCore, YIDU TECH has established a closed-loop flywheel of "data-algorithm-scenario," achieving high-efficiency innovation and low-cost scalable application of AI technology, empowering intelligent decision-making across the entire ecosystem of "healthcare-pharmaceutical-insurance-patients."

The core of AI healthcare lies in improving the quality and generation efficiency of medical evidence, optimizing research and development, diagnosis, and treatment processes, ultimately delivering safer, higher-quality, and more accessible medical services. YIDU TECH continuously enhances healthcare service efficiency and accessibility, providing doctors with more precise and efficient decision-making tools, helping pharmaceutical companies shorten the distance from molecules to patients, enabling patients to access more affordable precision diagnosis and treatment, and providing public systems with more scientific support.

The value of medical AI is reflected in the respect for every individual life and the protection of health and well-being.